, reducing ERK1/2 activation and VSMC proliferation in vitro. In contrast, EC proliferation inhibition by cAMP is independent from PKA modification of p85␣ and ERK1/2 inhibition; indeed, PKA-activated p85␣ did not inhibit per se ERK1/2 activation and proliferation in ECs in vitro. Interestingly, cAMP reduced both VSMC and EC apoptotic death through p85␣ phosphorylation. Accordingly, PKA-activated p85␣ triggered Akt activation, reducing both VSMC and EC apoptosis in vitro. Finally, compared with controls, vascular gene transfer of PKA-activated p85␣ significantly reduced neointimal formation after balloon injury in rats, without inhibiting endothelial regeneration of the injured arterial segment. In conclusions, PKA-activated p85␣ integrates cAMP/PKA signaling differently in VSMCs and ECs. By reducing neointimal hyperplasia without inhibiting endothelial regeneration, it exerts a protective effect against restenosis after balloon injury. smooth muscle cells; endothelial cells; adenosine 3Ј,5Ј-cyclic monophosphate; gene therapy DRUG-ELUTING STENTS (DES) have significantly changed interventional cardiology, owing to their remarkable ability to reduce restenosis compared with bare-metal stents (2, 19) . However, as incomplete reendothelialization after DES deployment seems to drive an increased risk for late thrombosis (24) , it has been suggested that DES should ideally have a selective anti-proliferative effect on vascular smooth muscle cells (VSMCs), but be inert toward endothelial cells (ECs) or, greater still, promote their proliferation (34) . The latter could be achieved by the identification of drugs/intracellular molecules that play differential roles on VSMC and EC growth.
In the last few years, our laboratory has shown that cAMP activates a PKA-dependent molecular pathway, culminating in VSMC growth inhibition in vitro and in vivo (15, 17, 20) . Elevation of cAMP in vascular ECs has been shown to inhibit proliferation (11) . However, while it reduces the proliferation of most cell types, cAMP has also been shown to promote the growth of few cell lineages, such as Swiss 3T3 fibroblasts and thyrocytes (1, 22, 23) . Indeed, cAMP exerts its multiple cellular effects, triggering different, sometimes opposing, molecular cascades (5) . In many, but not all, cell types, cAMP/PKA inhibits MAPK/ERK cascade (5) . In thyroid cells and NIH3T3 fibroblasts, cAMP phosphorylates p85␣, the regulatory subunit of phosphatidylinositol 3-kinase (PI3K) (p85␣ PI3K ), on serine 83 (Ser83) (6, 8) , inducing cell proliferation in thyroid cells (6) , while inhibiting cell growth in NIH3T3 fibroblasts (8) . cAMP/PKA-modified p85␣ promotes p21 ras -PI3K complex, amplifying PI3K signaling while reducing ERK1/2 activation (8) . However, how cAMP/PKA-modified p85␣ affects VSMC and EC growth is unknown.
Here we show that cAMP inhibits VSMC proliferation through the phosphorylation of (Ser83) p85␣, which forms an inhibitory complex with p21 ras , preventing ERK1/2 activation. On the other hand, cAMP-induced cell cycle inhibition of ECs is independent from cAMP/PKA modification of p85␣. In agreement with these differential effects of p85␣ on VSMCs and ECs in vitro, PKA-modified p85␣ gene transfer reduces neointimal formation without affecting endothelial regeneration in vivo after balloon injury in rats.
MATERIALS AND METHODS
See online supplemental data for expanded MATERIALS AND
METHODS.
Plasmid transfection and cell cultures. Plasmids carrying FLAGtagged p85␣-wild-type or its Ser83 mutated forms were obtained, as previously described (6, 8) (Supplemental Table 1 ). Plasmids' transfection was performed using FuGENE 6 Transfection Reagent (Roche). Rat aortic VSMCs (A-10) and rat aortic ECs were from ATCC and Cell Applications, respectively. Cell proliferation was evaluated by a bromodeoxyuridine (BrdU) assay, while cell apoptosis was detected using the TdT assay (Roche) (10, 31) .
Animal study design and experimental balloon injury. The animal study protocol was approved by the animal use committee of Magna Graecia University, Catanzaro, Italy. Balloon injury of the right carotid artery and plasmid transfections were performed in male Wistar rats, as described (16, 18) . VSMC proliferation, neointimal hyperplasia, and endothelial regeneration were carried out 14 days after balloon injury, as previously reported (18, 21) .
Statistical analysis. Data were analyzed using ANOVA, SPSS version 10.0. When a significant effect was detected, Bonferroni test was used to compare mean values. A P value of Ͻ0.05 was considered significant.
RESULTS
cAMP inhibits VSMC proliferation in vitro through PKA modification of p85␣. cAMP phosphorylates p85␣ PI3K at Ser83 in VSMCs (Fig. 1A) . Then we transfected rat VSMCs with FLAG-tagged plasmids carrying p85␣ PI3K wild type (p85 WT ), p85␣ PI3K Ser83-mutated with aspartic acid (to mimic this site PKA-dependent phosphorylation; p85 PKA-activated ), or with alanine (to prevent this site phosphorylation; p85 PKA-inactive ) (Supplemental Table 1 ). In addition, we silenced p85␣ PI3K with specific green fluorescence protein (GFP)-tagged small hairpin RNA (p85␣ shRNA ). Control (Con) cells were transfected with GFP plasmid.
p85
WT , p85 PKA-activated , p85 PKA-inactive , and GFP plasmids were efficiently transfected in VSMCs (Fig. 1B) . p85␣ shRNA plasmid was also efficiently transfected, and it reduced p85␣ protein expression in VSMCs (Fig. 1C) .
To evaluate cell proliferation, 48 h after plasmid transfection, VSMCs were serum starved for 48 h, and then cell growth was induced through incubation with 10% fetal bovine serum (serum stimulation) in the presence or absence of cAMP (8-bromoadenosine 3Ј,5Ј-cyclic monophosphate, a cAMP analog, 300 M) for 24 h. At the end of the starvation period, BrdU incorporation was similar across all p85␣ plasmid transfections and Con (data not shown). To simplify the presentation, we pooled these data together (base, Fig. 1D ). After 24 h of serum stimulation, treatment with cAMP reduced VSMC proliferation in Con cells (Fig. 1D) . Expression of p85 WT did not have an effect per se on VSMC proliferation; however, it did exacerbate the cAMP growth-inhibitory response (Fig.  1D) . p85
PKA-inactive did not affect VSMC growth, but it eliminated cAMP-induced cell proliferation inhibition (Fig. 1D) . Importantly, p85
PKA-activated decreased VSMC proliferation in the absence of cAMP, and cell proliferation in p85 PKA-activated transfected cells was further reduced in the presence of cAMP (Fig. 1D ). p85␣
shRNA had no effect per se on VSMC proliferation, but it did abolish the cAMP-dependent response (Fig. 1E) . As the p85␣ constructs were generated from bovine p85␣ cDNA, which shares a high rate of homology with human and rat sequences (8), we repeated these experiments in human and porcine coronary smooth muscle cells and observed similar results (data not shown).
These results demonstrate that cAMP/PKA reduce VSMC proliferation through p85␣ phosphorylation. Also, p85 gene transfer in vitro is able to reduce VSMC growth per se.
cAMP phosphorylates p85␣, which binds p21 ras and inhibits ERK1/2 phosphorylation in VSMCs. As p21 ras /ERK1/2 cascade is pivotal in inducing VSMC proliferation in vitro and in vivo (19) , we set to evaluate how PKA-mediated p85␣ (Ser83) phosphorylation regulates p21 ras -ERK1/2 cascade in VSMCs.
Forty-eight hours after plasmid transfection, p85␣ plasmid transfected VSMCs were serum starved for 24 h and then stimulated for 20 min with IGF-I (100 nM) or 10% fetal bovine serum with or without cAMP. IGF-I is a classical mitogen, which activates the p21 ras /ERK cascade (3). Stimulation of VSMCs with IGF-I did not induce p21 ras -p85␣ association and resulted in ERK1/2 phosphorylation in Con (GFP transfected), p85
WT , and p85 PKA-inactive transfected cells (Fig. 2, A and B) . On the other hand, transfected p85
PKA-activated coupled with p21 ras , and it reduced IGF-Iinduced ERK1/2 phosphorylation (Fig. 2, A ras from ERK1/2 activation to PI3K signaling in VSMCs. p85␣ plasmid transfected VSMCs, after a 24-h starvation period, were stimulated for 20 min with IGF-I or cAMP, and Akt phosphorylation was measured. Accordingly, IGF-I is also a well-known stimulator of PI3K/Akt pathway (3).
IGF-I resulted in Akt phosphorylation in Con VSMCs (Fig. 3, A and B). Expression of p85
WT and p85 PKA-inactive did not affect Akt phosphorylation upon IGF-I stimulation (Fig. 3, A  and B) . On the other hand, the expression of p85 PKA-activated induced Akt phosphorylation independently from the IGF-I stimulation (Fig. 3, A and B) . IGF-I stimulation further in- creased Akt phosphorylation in p85
PKA-activated -transfected VSMCs compared with Con (Fig. 3, A and B) .
Treatment with cAMP increased Akt phosphorylation in Con VSMCs (Fig. 3, C and D) . In response to cAMP, p85 WTtransfected VSMCs showed an increased Akt phosphorylation, compared with Con (Fig. 3, C and D) . p85
PKA-inactive overexpression reduced cAMP-mediated Akt phosphorylation (Fig. 3,  C and D) . Importantly, p85
PKA-activated increased Akt activation independently from cAMP (Fig. 3, C and D) . cAMP treatment increased Akt phosphorylation in p85 PKA-activated VSMCs, which was greater than in Con (Fig. 3, C and D) .
These results show that p85␣ PI3K mediates cAMP-dependent activation of PI3K/Akt pathway in VSMCs. Also, p85
PKA-activated promotes Akt activation per se. As PI3K/Akt is a well-known cascade regulating cell survival, and VSMC apoptosis contributes to vascular response to injury (26), we evaluated the role of cAMP/PKA/p85␣ signaling on H 2 O 2 -induced VSMC apoptosis in vitro.
cAMP reduced VSMC apoptosis in Con cells (Fig. 3E ). This cAMP cytoprotection was abolished by wortmannin, a PI3K/ Akt inhibitor (data not shown). Overexpression of p85 WT did not have any effect on H 2 O 2 -induced VSMC apoptosis (Fig.  3E) . However, cAMP-induced survival was improved by p85
WT transfection, compared with Con (Fig. 3E) . On the other hand, p85
PKA-inactive overexpression did not affect VSMC death, but it eliminated cAMP-mediated cell protection (Fig.  3E) . Importantly, p85
PKA-activated decreased VSMC apoptosis in the absence of cAMP, and cell death in p85
PKA-activated transfected VSMCs was further reduced by cAMP, compared with Con (Fig. 3E ). These data indicate that Ser83 phosphorylation of p85␣ PI3K mediates cAMP inhibition of VSMC death and that p85
PKA-activated has vascular protective effects per se in preventing VSMC apoptosis in vitro. cAMP inhibits EC proliferation in vitro independently from PKA-modification of p85␣ and ERK1/2 inhibition. cAMP stimulation phosphorylates p85␣ on Ser83 also in ECs (Fig. 4A) . We assessed the effects of cAMP/PKA modification of p85␣ PI3K on rat aortic ECs in vitro. p85 WT , p85 PKA-activated , p85
PKA-inactive , and GFP plasmids were efficiently transfected in ECs (Fig. 4, B and C) .
We then assessed cell proliferation in ECs transfected with p85
WT , p85 PKA-activated , and p85 PKA-inactive or GFP (Con) ( Table 1 ). After 36-h starvation (no serum), BrdU incorporation was similar across all plasmid transfections (data not shown), and we pooled the data together (base, Fig. 4D ). Twenty-four hours after serum stimulation, cAMP treatment reduced proliferation in Con ECs (Fig. 4D) . p85
WT and p85 PKA-inactive transfection did not affect EC proliferation, in the absence or presence of cAMP (Fig. 4D) . Remarkably, the expression of p85 PKA-activated did not affect EC proliferation, neither did it modify the cAMP response (Fig. 4D) . Similar results were obtained in human umbilical vein ECs (data not shown). These results demonstrate that cAMP inhibits EC proliferation in vitro independently from p85␣ modification. Accordingly, PKA-activated p85␣ does not affect EC growth in vitro.
Then, similar to VSMCs, we determined the effects of cAMP and the different p85␣ plasmids on p21 ras -p85␣ PI3K complex and ERK1/2 activation in ECs. cAMP promoted p21 ras -p85␣ PI3K complex, but this complex did not affect ERK1/2 phosphorylation in serum-stimulated Con ECs (Fig. 4, 
E and F). Overexpression of p85
WT did not affect p21 rasp85␣ PI3K complex and ERK phosphorylation in serum-stimulated conditions. Upon cAMP treatment, p21 ras -p85␣ PI3K complex increased, but ERK activation occurred normally in p85
WT -transfected compared with Con ECs (Fig. 4, E and F complex, the latter did not translate into any effect on ERK1/2 phosphorylation (Fig. 4, E and F) . Accordingly, transfected p85
PKA-activated coupled with p21 ras , but it did not reduce ERK1/2 phosphorylation, compared with Con ECs. cAMP further increased p21 ras -p85␣ PI3K complex, but this molecular switch had no consequences on ERK1/2 phosphorylation in p85 PKA-activated transfected ECs (Fig. 4, E and F) . Additionally, expression of p85
PKA-inactive , and p85 PKA-active did not affect ERK1/2 phosphorylation upon IGF-I stimulation, compared with Con ECs (Supplemental Fig. 1) .
These results show that cAMP-dependent growth inhibition of ECs is independent from p85␣ modification with its binding to p21 ras and ERK1/2 modulation. Accordingly, PKA-activated p85␣ does not inhibit ERK1/2 activation and cell proliferation in ECs in vitro.
cAMP inhibits EC apoptosis in vitro through PKA modification of p85␣ and Akt activation. Similar to how experiments were carried out with VSMCs, cAMP increased Akt phosphorylation also in Con ECs (Fig. 5, A and B) . In response to cAMP, p85 WT -transfected ECs showed an increased Akt phosphorylation compared with Con (Fig. 5, A and B) . In ECs transfected with p85 PKA-inactive , cAMP-induced Akt phosphorylation was reduced compared with Con (Fig. 5, A and B) . Importantly, the expression of p85 PKA-activated increased Akt phosphorylation in the absence of cAMP, and then, in the presence of cAMP, Akt phosphorylation increased further (Fig.  5, A and B) . Thus p85␣ PI3K mediates cAMP-dependent phosphorylation of Akt and p85 PKA-activated promotes Akt activation per se in ECs.
Then we evaluated the role of cAMP/PKA/p85␣ signaling on H 2 O 2 -induced apoptosis in ECs. Treatment with cAMP reduced EC apoptosis in Con (Fig. 5C ). cAMP cytoprotection was abolished by wortmannin, a PI3K/Akt inhibitor (data not shown). Expression of p85
WT did not have any effect on EC apoptosis (Fig. 5C ). However, cAMP treatment reduced apoptotic death in p85
WT -transfected ECs, compared with Con (Fig. 5C ). p85
PKA-inactive did not influence EC death; however, p85
PKA-inactive blunted cAMP-dependent cell protection (Fig. 5B) . Notably, p85
PKA-activated decreased EC apoptosis in the absence of cAMP, and this was further decreased in the presence of cAMP, compared with Con (Fig. 5C) .
Therefore, cAMP-induced EC survival is mediated by (Ser83) phosphorylation of p85␣ PI3K , and p85 PKA-activated overexpression reduces EC death per se.
Local delivery of p85 PKA-activated prevents VSMC proliferation and neointimal hyperplasia after experimental balloon injury. We determined the effects of the overexpression of the p85␣ PI3K plasmids in rat carotid arteries subjected to balloon injury. Using pluronic F127 gel, a sustained release polymer (16) , rat carotid arteries were locally transfected with FLAGtagged plasmid vectors expressing p85
WT , p85 PKA-inactive , and p85 PKA-activated immediately after balloon injury. Carotid arteries of Con rats were transfected with a GFP plasmid construct (Con). The latter has no effect per se on neointimal formation after balloon injury (data not shown). As additional controls, only saline was dissolved in the pluronic gel (Gel). Neointimal formation was analyzed 14 days after balloon injury (Table 1) .
Forty-eight hours after balloon injury, the expression of the exogenous plasmids in the carotid arteries was verified by immunofluorescence staining, immunoprecipitation, and Western blot analysis in five additional rats per group (Fig. 6, A and  B) . At this time point [when VSMC proliferation reaches its peak after balloon injury (31) ] in the carotid arteries treated with local transfection of p85 PKA-activated plasmid, a significant lower ratio of Ki-67-positive nuclei to total cells [proliferation PKA-activated (FLAG, green fluorescence). Blue fluorescence corresponds to nuclei staining by 4,6-diamidino-2-phenylindole (DAPI). B: Western blot for p85 (after IP with FLAG antibody) confirms the efficient transfection of the p85␣ constructs in the injured carotid arteries. C: in vivo proliferation index (Ki67 pos VSMCs-to-total VSMCs ratio) 2 days after balloon injury (BI). *P Ͻ 0.05 vs. all. D: VSMCs (SMA, red) positive for Ki67 (green) in the media layer 2 days after BI in Con and p85
PKA-activated -transfected rat carotid arteries. E and F: neointimal area and neointima-to-media ratio, respectively, 14 days after BI. *P Ͻ 0.05 vs. all. G: bright microscope images of representative histological carotid cross sections 14 days after BI from the different groups. A representative uninjured (No Injury) rat common carotid artery is included. index (PI) ϭ 4 Ϯ 2%] was observed, compared with carotid vessels with Con GFP plasmid (Con, PI ϭ 14 Ϯ 3%; P Ͻ 0.05) (Fig. 6, C and D) . No effects on VSMC proliferation were observed by the transfection of p85 WT or p85 PKA-inactive constructs (PI ϭ 15 Ϯ 4 and 14 Ϯ 4%, respectively) (Fig. 6C) . p85 PKA-activated expression significantly reduced neointimal hyperplasia 14 days after balloon injury, and neointimal tissue was reduced by ϳ55%, compared with the other groups (Table  1 and Fig. 6, E-G) . Neither p85
WT or p85 PKA-inactive had an effect on neointimal formation (Fig. 6, E-G) . p85 PKA-activated local delivery does not affect endothelial regeneration in rat balloon-injured arteries. Reendothelialization was assessed through quantitative immunohistochemistry with von Willebrand factor (vWF) staining and by planimetry analysis after Evans blue injection in vivo (21, 32) . At 14 days after balloon injury in Con, reendothelialization was minimal in the middle segment (%vWF stained, 24.5 Ϯ 5%), yet more complete at the proximal and distal segments (proximally, 74 Ϯ 3%; distally, 80 Ϯ 4%) (Fig. 7A) . This was expected due to the higher injury produced at middle arterial segment by the Fogarty-balloon dilation and back-and-forth passage (25) . Reendothelialization was similar to Con at these three vascular segments in the p85 PKA-activated transfected carotid arteries (%vWF stained, middle ϭ 28.5 Ϯ 4%, proximal ϭ 79.5 Ϯ 5%; distal ϭ 85 Ϯ 5%; P ϭ nonsignificant) (Fig. 7, A-C) . These data were confirmed by Evans blue planimetry analysis performed in an additional four rats per group (Fig. 7, D and E, and Supplemental Fig. 2 ).
DISCUSSION
The major findings of the present study are as follows. 1) cAMP inhibits VSMC proliferation through p85␣ (Ser83) phosphorylation. p85
PKA-activated gene transfer inhibits VSMC proliferation in vitro, through coupling with p21 ras and inhibition of ERK1/2 phosphorylation. 2) cAMP inhibits EC proliferation independently from p85␣ (Ser83) phosphorylation and ERK1/2 inhibition. Accordingly, p85
PKA-activated does not affect ERK1/2 activation and cell proliferation of ECs in vitro.
3) cAMP-induced cytoprotection on VSMCs and ECs depends on p85␣ (Ser83) phosphorylation. Hence, p85
PKA-activated attenuates apoptosis in vitro by amplifying Akt pathway activation in both vascular cell types. 4) Local gene transfer of p85 PKA-activated inhibits neointimal hyperplasia and does not hinder normal endothelial regeneration after balloon injury in rats.
The cellular and molecular mechanisms regulating restenosis after balloon dilation and/or stent deployment have been deeply investigated in the last decades (19) . VSMC proliferation is the main cellular event responsible for restenosis after PCI with stenting (2, 9, 19, 26) . The p21 ras /MAPKs cascade plays a central role in VSMC proliferation and p21 ras , as well as MAPKs inhibition prevents VSMC proliferation and neointimal formation after balloon injury (16, 19, 34) . In sharp contrast, increased cAMP levels inhibit VSMC proliferation in vitro and reduce neointimal formation after balloon injury in vivo (15, 17, 20, 29) . In most cell types, increasing intracellular cAMP concentration strongly inhibits cell growth and division (30) . The main mediator of the cAMP-dependent inhibitory effect on cell proliferation is PKA (19, 23, 35) , which has been reported to inhibit the p21 ras /ERK1/2 signaling pathway in several cell types (7, 25) . In striking contrast, PKA can also activate the ERK1/2 signaling pathway and still inhibit cell proliferation (4) . Surprisingly, we have shown that cAMPactivated PKA stimulates cell proliferation by inhibiting ERK1/2, thereby favoring activation of the PI3K signaling pathway in thyroid cells (6) . To complicate the matter, cAMP can also inhibit cell proliferation through the inhibition of ERK1/2 in a PKA-independent manner (13) . With regards to ECs, it is generally accepted that an increasing level of cAMP inhibits EC growth (11); also, cAMP differentially regulates EC function, depending on its intracellular compartmentalization (27) . However, the mechanisms underlying this cellular events are largely unknown.
PI3K enzyme is a heterodimeric protein, composed of separate regulatory (p85) and catalytic (p110) subunits (33) . The p85 regulatory subunit exists in different isoforms, namely p85␣, p85␤, and p50␣/p55␣, of which p85␣ is, by large, the most abundant. The p85␣ mediates the binding, activation, and localization of the PI3K enzyme (33) . Furthermore, recent evidence suggested that, in addition to being a regulatory subunit for p110-PI3K, p85 can independently stimulate signaling pathways (33) . In the present study, we found that cAMP/PKA-activated p85␣ stabilizes p21 ras in a molecular complex inhibiting mitogen-dependent ERK1/2 activation, which reduces VSMC proliferation in vivo and in vitro. On the other hand, overexpressing a mutated form of p85␣, PKA unphosphorylable (p85 PKA-inactive ), or p85␣ deletion by specific siRNA transfection abolished cAMP-induced growth inhibition in VSMCs. These data strongly support the view that p85␣ is a key modulator of cAMP/PKA molecular and cellular effects in VSMCs.
In contrast with the effects on VSMCs, we show that cAMP reduces EC proliferation in a p85␣-and ERK1/2-independent manner in vitro. Indeed, ERK1/2 was normally phosphorylated by serum stimulation, despite cAMP administration and the formation of the p85␣-p21 ras complex. Accordingly, p85
PKA-activated overexpression did not interfere with ERK1/2 activation on serum stimulation in ECs, and cell proliferation occurred normally in ECs overexpressing p85 PKA-activated . What is the key molecular target of cAMP mediating its cell proliferation inhibition in ECs remains unknown by now.
We also show that cAMP has cytoprotective effects on both VSMCs and ECs. cAMP reduced VSMC and EC apoptosis in association with Akt activation. Importantly, these cAMP effects were mediated through p85␣ (Ser83) phosphorylation in both vascular types.
Several studies have uncovered the existence of a molecular cross talk between PI3K/Akt and p21 ras /ERK signaling in modulating cell differentiation, proliferation, and survival (14) . More specifically to VSMCs, the cross talk entails an inhibitory effect of Akt on ERK1/2 through Raf modulation (28) . Thus, in VSMCs, PKA-activated p85␣ could inhibit ERK activation at two levels: by sequestering p21 ras and by activating Akt. However, in specific cell contexts, the cross talk between PI3K/Akt and GTPase Ras/ERK becomes synergistic in a molecular framework involving the activity of phospholipase C (PLC) (14) . Incidentally, PLC-ε (one of the PLC isoenzyme) is also a target of PKA-independent cAMP activity (12) . Thus it could be hypothesized that another kinase (like PLC) is effective in ECs, as opposed to VSMCs, in preserving ERK1/2 activation upon extracellular mitogen stimuli, despite p85␣ activation by cAMP/PKA. Nevertheless, it remains somewhat puzzling that VSMCs and ECs have an increased Akt activation when overexpressing p85␣ PKA-activated ; however, they still show a reduced or normal cell growth response, respectively. It could be that Akt activation levels obtained by p85␣ PKA-activated overexpression are sufficient to complete the Akt-dependent survival pathway, but are not enough to trigger the Akt-dependent cell cycle machinery. These mere speculations, of course, warrant further investigations.
Finally, we show that p85 PKA-activated transfection in the vascular wall significantly reduced VSMC proliferation in the tunica media upon balloon injury. This, in turn, resulted in a decreased neointimal formation at 14 days after balloon injury compared with Con rats. Also, p85␣
WT overexpression did not affect VSMC proliferation and neointima formation after balloon injury. The latter is most likely secondary to the reduced cAMP levels and the consequent PKA hypo-phosphorylation in proliferating VSMCs in response to vascular injury (15, 17) . Importantly, it was of interest to show that, in agreement with the in vitro experiments, p85
PKA-activated in vivo transfection did not adversely affect the endothelial regeneration in the balloon-injured common carotid arteries.
In conclusion, the data of the present study demonstrate that PKA-activated p85␣ has differential effects on VSMC and EC growth in vitro, and, when locally delivered, it inhibits neointimal formation without affecting endothelial repair after vascular injury in vivo. These findings could be of relevance to eventually translate PKA activation of p85␣ as a target for, or possibly a cDNA coding for PKA-activated p85␣ to be released by, DES to prevent restenosis without adding the hazard of lack of reendothelialization. 
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